SAN CARLOS, Calif., Dec. 9, 2013 /PRNewswire/ -- Rosa & Co. LLC is pleased to announce it has established an alliance with the KressWorks Foundation to develop a Ewing's Sarcoma PhysioPD Research Platform, a quantitative model of the physiologic and pharmacologic mechanisms involved in Ewing's Sarcoma. The Platform will be used to advance the development of treatments for Ewing's Sarcoma, a rare bone cancer that affects children and adolescents. The initial focus of the project is development of a PhysioMap® that portrays pathways involved in disease progression and current standards of care. The PhysioMap will serve as the formal architecture for the PhysioPD Platform, one of the essential components of the Systematic Treatment Methodology being developed by The KressWorks Foundation to provide a systematic, patient-specific methodology for the treatment of Ewing's Sarcoma.
"Rosa's unrivaled experience in the field of Quantitative Systems Pharmacology will support our Vision for the Future: to provide a significant improvement in the treatment of Ewing's Sarcoma by applying deterministic, physiological model/simulation-driven methods with clinical verification and application. This approach will provide advancement for more effective treatments and a more focused and direct approach to therapy", said Jim Kress, PhD, President of The KressWorks Foundation.
"We are excited to be working with The KressWorks Foundation to improve the current understanding of Ewing's Sarcoma. This alliance will generate a solid mechanistic rationale for guiding treatment options and clinical decisions for patients and physicians," said Dr. Ron Beaver, PhD, Rosa's Cofounder, Chairman, and CEO.
Rosa aids clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of R&D related challenges, Rosa offers customized approaches: pharmacokinetic/pharmacodynamic models and Rosa's innovative PhysioPD models. Rosa's clients participate in customized model creation, testing, and research, retain the models, and acquire the models to perform model research to inform decisions and better understand implications for their drug development programs. Rosa's staff has unparalleled professional experience in applying modeling and simulation to accelerate drug development and have completed hundreds of engagements with clients in virtually all therapeutic areas, including metabolism, oncology, immunology, neurology, and dermatology. For more information, visit www.rosaandco.com.
Sharan Pagano 978-995-2805
The KressWorks Foundation is a nonprofit, 501(c) (3) Scientific and Engineering research corporation that researches, develops, and applies practical, effective technologies and methodologies to the improvement of the Human Condition. Its primary focus is to deliver an effective and systematic methodology that provides optimal treatment regimens for patients suffering from Ewing's Sarcoma and is extensible to other forms of cancer and other diseases.
This work is funded, in part, by a generous $20,000 donation by Mobility Transportation Services of Canton, MI (http://www.mobilitytrans.com/about_us/index.php).
For more information about The KressWorks Foundation, visit http://www.kressworks.org.
James Kress 248-605-8770
Read more news from Rosa and The KressWorks Foundation.
SOURCE Rosa and The KressWorks Foundation